{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-negative+Breast+Cancer", "query": { "condition": "HER2-negative Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 788, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-negative+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T08:57:04.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02384746", "title": "Phase I Study of the Combination of MLN9708 and Fulvestrant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "MLN9708", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2015-06-02", "completion_date": "2018-06-10", "has_results": false, "last_update_posted_date": "2019-04-29", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384746" }, { "nct_id": "NCT05501769", "title": "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ARV-471 in combination with Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Estrogen Receptor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2022-09-08", "completion_date": "2025-08-25", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 6, "location_summary": "San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501769" }, { "nct_id": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer", "Breast Cancer Stage", "Recurrent Breast Cancer", "Metastatic Breast Cancer", "HER2 Positive Breast Carcinoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-12-06", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 16, "location_summary": "Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530696" }, { "nct_id": "NCT05660083", "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer", "Metastatic Breast Cancer", "Metaplastic Breast Carcinoma", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-01-12", "completion_date": "2028-12-02", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660083" }, { "nct_id": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Hematologic Neoplasms", "Ovarian Cancer", "HER2-positive Advanced Solid Tumors", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Cervical Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "tebotelimab 1 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 3 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 10 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 30 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 120 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 300 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 400 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 600 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 800 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 1200 mg", "type": "BIOLOGICAL" }, { "name": "margetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2017-08-18", "completion_date": "2023-02-08", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219268" }, { "nct_id": "NCT07426822", "title": "Rash & Diarrhea Prophylaxis With Capivasertib", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic HR+/HER2- Breast Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ceterizine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Maryam Lustberg", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2026-04", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07426822" }, { "nct_id": "NCT01421472", "title": "A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ER Positive, Her2 Negative Breast Cancer Patients", "Triple Negative Breast Cancer Patients" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 196, "start_date": "2011-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-05-03", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421472" }, { "nct_id": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Malignant Female Reproductive System Neoplasm", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Unresectable HER2-Negative Breast Carcinoma", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Nilotinib Hydrochloride Monohydrate", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2900, "start_date": "2023-04-07", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 475, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564377" }, { "nct_id": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Saruparib (AZD5305)", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-08-01", "completion_date": "2030-10-18", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Fountain Valley, California • Glendale, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06380751" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-07T08:57:04.128Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" } ] }